Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330646
A. Chockalingam, V. Tyagi, R. Krishnan, Shehroz S. Khan, Sarath Chandar, M. Beg, V. Mahajan, Parasvil Patel, S. Mullapudi, N. Thakkar, Arrti Bhasin, A. Tyagi, B. Ye, Alex Mihailidis
Artificial intelligence (AI) has a great impact on our daily living and makes our lives more efficient and productive. Especially during the coronavirus disease (COVID-19) pandemic, AI has played a key role in response to the global health crisis. There has been a boom in AI innovation and its use since the pandemic. However, despite its widespread adoption and great potential, most people have little knowledge of AI concepts and realization of its potential. The objective of this white paper is to communicate the importance of AI and its benefits to society. The report covers AI applications in six different topics from medicine (AI deployment in clinical settings, imaging and diagnostics, and acceleration of drug discovery) to more social aspects (support older adults in long-term care homes, and AI in supporting small and medium enterprises. The report ends with nine steps to consider for moving forward with AI implementation during and post pandemic period. These include legal and ethical data collection and storage, greater data access, multidisciplinary collaboration, and policy reform.
{"title":"Artificial intelligence and its contribution to overcome COVID-19","authors":"A. Chockalingam, V. Tyagi, R. Krishnan, Shehroz S. Khan, Sarath Chandar, M. Beg, V. Mahajan, Parasvil Patel, S. Mullapudi, N. Thakkar, Arrti Bhasin, A. Tyagi, B. Ye, Alex Mihailidis","doi":"10.4103/2468-8827.330646","DOIUrl":"https://doi.org/10.4103/2468-8827.330646","url":null,"abstract":"Artificial intelligence (AI) has a great impact on our daily living and makes our lives more efficient and productive. Especially during the coronavirus disease (COVID-19) pandemic, AI has played a key role in response to the global health crisis. There has been a boom in AI innovation and its use since the pandemic. However, despite its widespread adoption and great potential, most people have little knowledge of AI concepts and realization of its potential. The objective of this white paper is to communicate the importance of AI and its benefits to society. The report covers AI applications in six different topics from medicine (AI deployment in clinical settings, imaging and diagnostics, and acceleration of drug discovery) to more social aspects (support older adults in long-term care homes, and AI in supporting small and medium enterprises. The report ends with nine steps to consider for moving forward with AI implementation during and post pandemic period. These include legal and ethical data collection and storage, greater data access, multidisciplinary collaboration, and policy reform.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42284446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330655
Chocko Valliappa, R. S. Sabeenian, M. Paramasivam, Eldho Paul, K. Manju, R. Pragadeesh
Vocal cord paralysis is a common problem faced by individuals, where the vocal cord fails to reverberate to produce sound waves. As a result, they are unable to speak out as they were speaking before. The proposed method is designed for aiding unilateral paralyzed peoples whose vocal cord fails to give the desired reverberations. The proposed system consists of voice-to-text and text-to-voice conversions. The voice of the paralyzed person is artificially reproduced by training a deep neural network with the unaffected voice of the patient. The confidence of the predicted output is improved by introducing voice-to-text conversion block along with the deep neural network. The performance metrics reveals the effectiveness of the proposed algorithm to reproduce natural sound. The similarity index is also high compared to that of other state-of-the-art techniques.
{"title":"Voice support system using deep learning approaches for unilateral vocal cord paralyzed patients","authors":"Chocko Valliappa, R. S. Sabeenian, M. Paramasivam, Eldho Paul, K. Manju, R. Pragadeesh","doi":"10.4103/2468-8827.330655","DOIUrl":"https://doi.org/10.4103/2468-8827.330655","url":null,"abstract":"Vocal cord paralysis is a common problem faced by individuals, where the vocal cord fails to reverberate to produce sound waves. As a result, they are unable to speak out as they were speaking before. The proposed method is designed for aiding unilateral paralyzed peoples whose vocal cord fails to give the desired reverberations. The proposed system consists of voice-to-text and text-to-voice conversions. The voice of the paralyzed person is artificially reproduced by training a deep neural network with the unaffected voice of the patient. The confidence of the predicted output is improved by introducing voice-to-text conversion block along with the deep neural network. The performance metrics reveals the effectiveness of the proposed algorithm to reproduce natural sound. The similarity index is also high compared to that of other state-of-the-art techniques.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47257099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330653
Deepa Krishnaswamy, Salehe Erfanian Ebadi, Seyed Ehsan Seyed Bolouri, D. Zonoobi, Russ Greiner, Nathaniel Meuser-Herr, J. Jaremko, J. Kapur, M. Noga, K. Punithakumar
Context: Efficiently diagnosing COVID-19-related pneumonia is of high clinical relevance. Point-of-care ultrasound allows detecting lung conditions via patterns of artifacts, such as clustered B-lines. Aims: The aim is to classify lung ultrasound videos into three categories: Normal (containing A-lines), interstitial abnormalities (B-lines), and confluent abnormalities (pleural effusion/consolidations) using a semi-automated approach. Settings and Design: This was a prospective observational study using 1530 videos in 300 patients presenting with clinical suspicion of COVID-19 pneumonia, where the data were collected and labeled by human experts versus machine learning. Subjects and Methods: Experts labeled each of the videos into one of the three categories. The labels were used to train a neural network to automatically perform the same classification. The proposed neural network uses a unique two-stream approach, one based on raw red-green-blue channel (RGB) input and the other consisting of velocity information. In this manner, both spatial and temporal ultrasound features can be captured. Statistical Analysis Used: A 5-fold cross-validation approach was utilized for the evaluation. Cohen's kappa and Gwet's AC1 metrics are calculated to measure the agreement with the human rater for the three categories. Cases are also divided into interstitial abnormalities (B-lines) and other (A-lines and confluent abnormalities) and precision-recall and receiver operating curve curves created. Results: This study demonstrated robustness in determining interstitial abnormalities, with a high F1 score of 0.86. For the human rater agreement for interstitial abnormalities versus the rest, the proposed method obtained a Gwet's AC1 metric of 0.88. Conclusions: The study demonstrates the use of a deep learning approach to classify artifacts contained in lung ultrasound videos in a robust manner.
{"title":"A novel machine learning-based video classification approach to detect pneumonia in COVID-19 patients using lung ultrasound","authors":"Deepa Krishnaswamy, Salehe Erfanian Ebadi, Seyed Ehsan Seyed Bolouri, D. Zonoobi, Russ Greiner, Nathaniel Meuser-Herr, J. Jaremko, J. Kapur, M. Noga, K. Punithakumar","doi":"10.4103/2468-8827.330653","DOIUrl":"https://doi.org/10.4103/2468-8827.330653","url":null,"abstract":"Context: Efficiently diagnosing COVID-19-related pneumonia is of high clinical relevance. Point-of-care ultrasound allows detecting lung conditions via patterns of artifacts, such as clustered B-lines. Aims: The aim is to classify lung ultrasound videos into three categories: Normal (containing A-lines), interstitial abnormalities (B-lines), and confluent abnormalities (pleural effusion/consolidations) using a semi-automated approach. Settings and Design: This was a prospective observational study using 1530 videos in 300 patients presenting with clinical suspicion of COVID-19 pneumonia, where the data were collected and labeled by human experts versus machine learning. Subjects and Methods: Experts labeled each of the videos into one of the three categories. The labels were used to train a neural network to automatically perform the same classification. The proposed neural network uses a unique two-stream approach, one based on raw red-green-blue channel (RGB) input and the other consisting of velocity information. In this manner, both spatial and temporal ultrasound features can be captured. Statistical Analysis Used: A 5-fold cross-validation approach was utilized for the evaluation. Cohen's kappa and Gwet's AC1 metrics are calculated to measure the agreement with the human rater for the three categories. Cases are also divided into interstitial abnormalities (B-lines) and other (A-lines and confluent abnormalities) and precision-recall and receiver operating curve curves created. Results: This study demonstrated robustness in determining interstitial abnormalities, with a high F1 score of 0.86. For the human rater agreement for interstitial abnormalities versus the rest, the proposed method obtained a Gwet's AC1 metric of 0.88. Conclusions: The study demonstrates the use of a deep learning approach to classify artifacts contained in lung ultrasound videos in a robust manner.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47546417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330651
A. Boulet
Coronavirus disease 2019 (COVID-19) pandemic has caused the millions of deaths worldwide. Much of the mortality has been associated with a cytokine storm syndrome in patients admitted to the hospital with acute respiratory distress syndrome. Vast arrays of anti-inflammatory therapies are being explored to decrease the cytokine storm to save the lives. None of these therapies have demonstrated efficacy at all stages of the disease thus underlining its complexity. The current vaccine approach is challenged by the emerging virus variants. A multi-target approaches have been used with success for human immunodeficiency virus and some types of cancer. It has been recently proposed to use the same strategy for COVID-19. With their polymolecular structure, botanical drugs may offer an option within that strategy. Thykamine™, a novel botanical drug, with demonstrated anti-inflammatory, antioxidant, and immunomodulatory effects may become the part of the therapeutic arsenal against COVID-19.
{"title":"Coronavirus disease 2019: The prospect for botanical drug's polymolecular approach","authors":"A. Boulet","doi":"10.4103/2468-8827.330651","DOIUrl":"https://doi.org/10.4103/2468-8827.330651","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) pandemic has caused the millions of deaths worldwide. Much of the mortality has been associated with a cytokine storm syndrome in patients admitted to the hospital with acute respiratory distress syndrome. Vast arrays of anti-inflammatory therapies are being explored to decrease the cytokine storm to save the lives. None of these therapies have demonstrated efficacy at all stages of the disease thus underlining its complexity. The current vaccine approach is challenged by the emerging virus variants. A multi-target approaches have been used with success for human immunodeficiency virus and some types of cancer. It has been recently proposed to use the same strategy for COVID-19. With their polymolecular structure, botanical drugs may offer an option within that strategy. Thykamine™, a novel botanical drug, with demonstrated anti-inflammatory, antioxidant, and immunomodulatory effects may become the part of the therapeutic arsenal against COVID-19.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49196319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330644
A. Chockalingam, S. Kalyanasundaram
{"title":"Noncommunicable diseases in the age of pandemics","authors":"A. Chockalingam, S. Kalyanasundaram","doi":"10.4103/2468-8827.330644","DOIUrl":"https://doi.org/10.4103/2468-8827.330644","url":null,"abstract":"","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48100525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330649
V. Murty, Brian T Schwartz, R. Dembo, J. Thakur, Arrti Bhasin, A. Chockalingam
We present some recent activity in Ontario on the mathematical modeling of COVID-19 and the development of optimal strategies for vaccine distribution that take into account equity issues.
我们介绍了安大略省最近在新冠肺炎数学模型和制定考虑公平问题的疫苗分配最佳策略方面的一些活动。
{"title":"Modeling pandemics and vaccine and equity issues","authors":"V. Murty, Brian T Schwartz, R. Dembo, J. Thakur, Arrti Bhasin, A. Chockalingam","doi":"10.4103/2468-8827.330649","DOIUrl":"https://doi.org/10.4103/2468-8827.330649","url":null,"abstract":"We present some recent activity in Ontario on the mathematical modeling of COVID-19 and the development of optimal strategies for vaccine distribution that take into account equity issues.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48225930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330656
F. Diaz-Mitoma
Vaccination is the most effective approach in preventing and controlling the global public health threat of infectious diseases. Enveloped virus-like particles (eVLPs) offer advantages over other subunit vaccines because of their self-adjuvanting properties. Their optimal size and particulate structure activate antigen-presenting cells. The flexibility in manufacturing, applications, and advantages for preventing or treating disease are highlighted by the vaccine candidates described in this review. Previous preclinical and clinical studies demonstrated the immunogenicity of two eVLP vaccine candidates designed to protect against cytomegalovirus. The expression of viral envelope proteins in the eVLPs induces a robust neutralizing antibody response, which is considered a correlate of protection in many viral infections. VBI has developed two vaccine candidates against SARS CoV2, VBI-2902a, and VBI-2905a. Ongoing clinical development of these vaccine candidates will assess human safety and immunogenicity, after one or two doses in previously vaccinated and unvaccinated, individuals (NCT04773665).
{"title":"Enveloped virus-like particles as a platform for vaccine development","authors":"F. Diaz-Mitoma","doi":"10.4103/2468-8827.330656","DOIUrl":"https://doi.org/10.4103/2468-8827.330656","url":null,"abstract":"Vaccination is the most effective approach in preventing and controlling the global public health threat of infectious diseases. Enveloped virus-like particles (eVLPs) offer advantages over other subunit vaccines because of their self-adjuvanting properties. Their optimal size and particulate structure activate antigen-presenting cells. The flexibility in manufacturing, applications, and advantages for preventing or treating disease are highlighted by the vaccine candidates described in this review. Previous preclinical and clinical studies demonstrated the immunogenicity of two eVLP vaccine candidates designed to protect against cytomegalovirus. The expression of viral envelope proteins in the eVLPs induces a robust neutralizing antibody response, which is considered a correlate of protection in many viral infections. VBI has developed two vaccine candidates against SARS CoV2, VBI-2902a, and VBI-2905a. Ongoing clinical development of these vaccine candidates will assess human safety and immunogenicity, after one or two doses in previously vaccinated and unvaccinated, individuals (NCT04773665).","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46533580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330658
J. Thakur, H. Kaur
India, being the biggest producer of drugs including vaccines, emerged as a major supplier of the coronavirus vaccines for most of the countries across the world during the COVID-19 pandemic. Two vaccines, Covishield and Covaxin, were given emergency use authorization by India's drugs regulator during initial phases. Under the guidance of the National Expert Group on Vaccine Administration for COVID-19, India started its national vaccination program against SARS-CoV-2 on January 16, 2021. CoWIN (COVID-19 Vaccine Intelligence Network) is playing a vital role in real-time monitoring of COVID-19 vaccination. Having a robust Universal Immunization Program and experience of the previous immunization campaigns are advantages for India's COVID-19 vaccination program. Under Vaccine Maitri initiative, India is providing vaccines to nations across the world to ensure vaccine equity. In India, vaccination is being done in a phased manner where priority is given to the health and other frontline workers, people with age >50 years and people with comorbidities and above 18 years. As per the current policy, center government is responsible for buying 75% of all vaccines made for use in India and will distribute it to states based on their populations, disease burdens, and number of people to be vaccinated. Remaining 25% vaccines are available to be procured by private hospitals. However, existing facilities seem to be unable to meet the increased demand, and the government is considering approval for other vaccines to be imported. The world, including India, is still fighting against COVID-19 and vaccine equity is very important to win against this pandemic.
{"title":"Vaccine distribution for COVID-19 and equity issues in India","authors":"J. Thakur, H. Kaur","doi":"10.4103/2468-8827.330658","DOIUrl":"https://doi.org/10.4103/2468-8827.330658","url":null,"abstract":"India, being the biggest producer of drugs including vaccines, emerged as a major supplier of the coronavirus vaccines for most of the countries across the world during the COVID-19 pandemic. Two vaccines, Covishield and Covaxin, were given emergency use authorization by India's drugs regulator during initial phases. Under the guidance of the National Expert Group on Vaccine Administration for COVID-19, India started its national vaccination program against SARS-CoV-2 on January 16, 2021. CoWIN (COVID-19 Vaccine Intelligence Network) is playing a vital role in real-time monitoring of COVID-19 vaccination. Having a robust Universal Immunization Program and experience of the previous immunization campaigns are advantages for India's COVID-19 vaccination program. Under Vaccine Maitri initiative, India is providing vaccines to nations across the world to ensure vaccine equity. In India, vaccination is being done in a phased manner where priority is given to the health and other frontline workers, people with age >50 years and people with comorbidities and above 18 years. As per the current policy, center government is responsible for buying 75% of all vaccines made for use in India and will distribute it to states based on their populations, disease burdens, and number of people to be vaccinated. Remaining 25% vaccines are available to be procured by private hospitals. However, existing facilities seem to be unable to meet the increased demand, and the government is considering approval for other vaccines to be imported. The world, including India, is still fighting against COVID-19 and vaccine equity is very important to win against this pandemic.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49231285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330645
V. Lakshmanan, A. Chockalingam, S. Kalyanasundaram
The Canada India Health-care Summit 2021, (“CIHS 2021”), is the 3rd Summit, focusing on healthcare, organized by Canada India Foundation, as part of an ongoing series of thematic Canada India Forums, to highlight opportunities for collaboration between Canada and India in key strategic sectors and make public policy recommendations to the respective governments. The Federation of Indian Chambers of Commerce and Industry, Toronto Rehabilitation Institute – University Health Network and the Consulate General of India in Toronto were co-organizers of the Summit. CIHS 2021 was focused on three themes: (1) artificial intelligence and its contribution to overcome COVID-19, (2) biotechnology and its contribution to overcome COVID-19, and (3) pandemic responses and initiatives. The Summit was held on May 20, 2021– May 21, 2021, and was preceded by three webinars. More than 60 healthcare experts and government leaders spoke at the Summit, to nearly 500 virtual attendees. A full report of the Summit with specific policy recommendations was made to the Canadian and Indian governments.
{"title":"Canada India Healthcare Summit 2021: Executive Overview","authors":"V. Lakshmanan, A. Chockalingam, S. Kalyanasundaram","doi":"10.4103/2468-8827.330645","DOIUrl":"https://doi.org/10.4103/2468-8827.330645","url":null,"abstract":"The Canada India Health-care Summit 2021, (“CIHS 2021”), is the 3rd Summit, focusing on healthcare, organized by Canada India Foundation, as part of an ongoing series of thematic Canada India Forums, to highlight opportunities for collaboration between Canada and India in key strategic sectors and make public policy recommendations to the respective governments. The Federation of Indian Chambers of Commerce and Industry, Toronto Rehabilitation Institute – University Health Network and the Consulate General of India in Toronto were co-organizers of the Summit. CIHS 2021 was focused on three themes: (1) artificial intelligence and its contribution to overcome COVID-19, (2) biotechnology and its contribution to overcome COVID-19, and (3) pandemic responses and initiatives. The Summit was held on May 20, 2021– May 21, 2021, and was preceded by three webinars. More than 60 healthcare experts and government leaders spoke at the Summit, to nearly 500 virtual attendees. A full report of the Summit with specific policy recommendations was made to the Canadian and Indian governments.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41937785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.4103/2468-8827.330648
M. Farkouh, Arrti Bhasin, D. Ko, Aviral Roy, I. Khurana, A. Chockalingam
This white paper will summarize the key topics, outcomes, and recommendations from the Canada-India Healthcare Summit 2021 COVID-19 Pandemic Response and Initiatives sessions held on May 20–21, 2021. In particular, the authors have focused their attention on topics on the effect of COVID-19 on noncommunicable diseases, depression, research on substance abuse, and post COVID-19 pain management. The authors have developed a better understanding of these conditions' interplay with COVID-19 infection. The paper also deals with important topics around the effects of NCD on COVID-19 and vice versa, as well as key considerations around research and development, innovation, policy, and finally, summarizes the ways forward in which Canada and India could collaborate strategically. We also include key points raised during the summit.
{"title":"Chronic noncommunicable diseases and COVID-19: How they both interact","authors":"M. Farkouh, Arrti Bhasin, D. Ko, Aviral Roy, I. Khurana, A. Chockalingam","doi":"10.4103/2468-8827.330648","DOIUrl":"https://doi.org/10.4103/2468-8827.330648","url":null,"abstract":"This white paper will summarize the key topics, outcomes, and recommendations from the Canada-India Healthcare Summit 2021 COVID-19 Pandemic Response and Initiatives sessions held on May 20–21, 2021. In particular, the authors have focused their attention on topics on the effect of COVID-19 on noncommunicable diseases, depression, research on substance abuse, and post COVID-19 pain management. The authors have developed a better understanding of these conditions' interplay with COVID-19 infection. The paper also deals with important topics around the effects of NCD on COVID-19 and vice versa, as well as key considerations around research and development, innovation, policy, and finally, summarizes the ways forward in which Canada and India could collaborate strategically. We also include key points raised during the summit.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49457231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：